OS Therapies (NYSE-A: OSTX) ("OS Therapies" or "the Company"), a clinical-stage immunotherapy and Antibody Drug Conjugate (ADC) biopharmaceutical company, today provided a regulatory update for its ...
The Japanese Ministry of Health, Labour and Welfare on Thursday approved Genmab A/S’ (NASDAQ:GMAB) Tivdak (tisotumab vedotin) ...
Bioconjugation presents an new frontier for pharmaceutical development, providing an option for improved drug efficacy across ...
ADC Therapeutics' primary focus is on the CD19-targeted antibody-drug conjugate Zynlonta. Read why ADCT stock is rated as a ...
Q4 2024 Earnings Call Transcript March 27, 2025 Innate Pharma S.A. misses on earnings expectations. Reported EPS is $-0.33474 ...
ConferenceHeidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025 26.03.2025 / 09:23 CET/CESTThe issuer is solely responsible for the content of this ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
This first FDA antibody-drug conjugate (ADC)-approval for platinum-resistant ovarian cancer indication covers those patients who have undergone one to three prior systemic treatment regimens ...
ADC Therapeutics could claim its first product approval in the US next May, after the FDA started a priority review of lead drug Lonca for diffuse large B-cell lymphoma (DLBCL), an aggressive form ...
AbbVie claims that Genmab turned a blind eye to trade secret theft allegedly used to support the development of ProfoundBio’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback